From Vascular Smooth Muscle Cells to Folliculogenesis: What About Vasorin?

Anne-Laure Bonnet; Anne-Laure Bonnet; Catherine Chaussain; Catherine Chaussain; Isabelle Broutin; Gaël Y. Rochefort; Heinrich Schrewe; Céline Gaucher; Céline Gaucher

doi:10.3389/fmed.2018.00335

Frontiers in Medicine (Dec 2018)

From Vascular Smooth Muscle Cells to Folliculogenesis: What About Vasorin?

Anne-Laure Bonnet,
Anne-Laure Bonnet,
Catherine Chaussain,
Catherine Chaussain,
Isabelle Broutin,
Gaël Y. Rochefort,
Heinrich Schrewe,
Céline Gaucher,
Céline Gaucher

Affiliations

Anne-Laure Bonnet: EA 2496 Orofacial Pathologies, Imaging and Biotherapies, Dental School Faculty, University Paris Descartes and Life Imaging Platform (PIV), Montrouge, France
Anne-Laure Bonnet: Department of Odontology, University Hospitals Charles Foix, PNVS, and Henri Mondor, AP-HP, Paris, France
Catherine Chaussain: EA 2496 Orofacial Pathologies, Imaging and Biotherapies, Dental School Faculty, University Paris Descartes and Life Imaging Platform (PIV), Montrouge, France
Catherine Chaussain: Department of Odontology, University Hospitals Charles Foix, PNVS, and Henri Mondor, AP-HP, Paris, France
Isabelle Broutin: Laboratoire de Cristallographie et RMN Biologiques (UMR 8015, CNRS), Pharmacy Faculty, University Paris Descartes, USPC, Paris, France
Gaël Y. Rochefort: EA 2496 Orofacial Pathologies, Imaging and Biotherapies, Dental School Faculty, University Paris Descartes and Life Imaging Platform (PIV), Montrouge, France
Heinrich Schrewe: Department of Developmental Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany
Céline Gaucher: EA 2496 Orofacial Pathologies, Imaging and Biotherapies, Dental School Faculty, University Paris Descartes and Life Imaging Platform (PIV), Montrouge, France
Céline Gaucher: Department of Odontology, University Hospitals Charles Foix, PNVS, and Henri Mondor, AP-HP, Paris, France

DOI: https://doi.org/10.3389/fmed.2018.00335
Journal volume & issue: Vol. 5

Abstract

Read online

First described in 1988, vasorin (VASN) is a transmembrane glycoprotein expressed during early mouse development, and with a less extent, in various organs and tissues (e.g., kidney, aorta, and brain) postnatally. Vasn KO mice die after 3 weeks of life from unknown cause(s). No human disease has been associated with variants of this gene so far, but VASN seems to be a potential biomarker for nephropathies and tumorigenesis. Its interactions with the TGF-β and Notch1 pathways offer the most serious assumptions regarding VASN functions. In this review, we will describe current knowledge about this glycoprotein and discuss its implication in various organ pathophysiology.

Published in Frontiers in Medicine

ISSN: 2296-858X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Medicine (General)
Website: http://www.frontiersin.org/journals/medicine

About the journal

Abstract

Keywords